<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="cd20neg-rrbnhl-mb-all-vinti">
    <meta name="study:title" content="PB3356 - CD20-negative relapsed/refractory mature B-cell non-Hodgkin lymphomas (B-NHLs) and mature B-cell leukemia in children, adolescents, and young adults: A retrospective review">
    <meta name="study:fileName" content="Abstracts/CD20-NEG-BNHL-MB-ALL-VINTI-PB3356.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Rituximab,Monoclonal Antibody,Chemotherapy,CIT">

    <title>PB3356: CD20-negative R/R B-NHL/mB-ALL in children/YA (Vinti) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3356 - CD20-negative relapsed/refractory mature B-cell malignancies in young patients</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848-.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=27)</h4>
                    <p>Children/Young Adults (YA) with R/R B-NHLs/mB-ALL. Aim: Evaluate CD20 expression at relapse & its impact on outcomes.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Methods (Retrospective Review)</h4>
                    <p>Data from 12 Italian Centers (past 10 yrs). CD20 status by IHC/flow at relapse. Most (24/27) prior Rituximab.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Finding: CD20 Loss at Relapse</h4>
                    <p><span class="highlight-value">40.7%</span> (11/27) showed CD20 loss at relapse (vs. 100% CD20+ at Dx). Most relapses <100 days post-Tx.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Outcome & Conclusion</h4>
                    <p>CD20-loss assoc. with more aggressive disease & worse outcome. Histological re-eval crucial for targeted Tx.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3356 - CD20-negative relapsed/refractory mature B-cell non-Hodgkin lymphomas (B-NHLs) and mature B-cell leukemia in children, adolescents, and young adults: A retrospective review</h1>
            <p class="abstract-sub-header">Luciana Vinti, Jolanda Pianese, Daniela Onofrillo, Irene D'Alba, Raffaella De Santis, Veronica Barat, Elisabetta Schiavello, Paola Muggeo, Concetta Micalizzi, Katia Perruccio, Valentina Bertaina, Lara Mussolin, Elisa Carraro, Luca Lo Nigro, Barbara Buldini, Rita De Vito, Marta Pillon, Franco Locatelli</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3356 | Publication Only</p>
        </div>

        <div id="abstractMainContent" class="grid md:grid-cols-12 gap-x-8 gap-y-6">
            <div class="md:col-span-8">
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>The most common pediatric types of mature B-cell non-Hodgkin malignancies are: Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and mature B-cell acute lymphoblastic leukemia (mB-ALL).</li>
                        <li>An increased event-free survival (EFS) and overall survival (OS) has been observed in patients with mature B-NHLs/mB-ALL receiving rituximab in addition to chemotherapy.</li>
                        <li>Despite the excellent cure rate at diagnosis, prognosis remains dismal in case of relapsed/resistant (R/R) disease.</li>
                        <li>Standard-of-care reinduction strategy is yet to be identified.</li>
                        <li>Several novel agents with activity against B-NHL are in development, including monoclonal and bispecific CD20-CD3 antibodies.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">Although the mechanism of resistance is unknown, the loss of CD20 expression in the R/R population could have a key role in the subsequent response. The aim of this updated retrospective study is the evaluation of CD20-expression by immunohistochemistry and/or flow cytometry in these neoplasms.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Data was retrospectively collected from children and young adults with R/R B-NHLs/mB-ALL and biopsy-proven CD20 status, treated in 12 Italian Centers in the past 10 years.</li>
                        <li>Patients were identified through individual sites querying local databases.</li>
                        <li>Biopsy/cytological evaluation was performed at disease progression or whenever possible for confirmation of disease and CD20-expression evaluation, and compared with diagnostic samples.</li>
                    </ul>
                </div>
            </div>

            <div class="md:col-span-4">
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics & CD20 Status (N=27)</h2>
                    <div class="table-container compact-table">
                        <table>
                            <thead><tr><th>Characteristic</th><th>Value</th></tr></thead>
                            <tbody>
                                <tr><td>Median Age at Diagnosis, years (range)</td><td>11.4 (4.1-19.3)</td></tr>
                                <tr><td>Median Age at Relapse, years (range)</td><td>12.3 (4.6-21.3)</td></tr>
                                <tr><td>Diagnoses</td><td>Burkitt (most common), DLBCL, mB-ALL, PMBCL</td></tr>
                                <tr><td>Prior Rituximab Received, n (%)</td><td>24 (88.9%)</td></tr>
                                <tr><td>Median Rituximab Infusions (range)</td><td>6 (0-8)</td></tr>
                                <tr><td>Relapse <100 days post last Tx, n (%)</td><td>20 (74.1%)</td></tr>
                                <tr><td>Median Time from last Tx to Relapse, months (range)</td><td>1.8 (0.1-66)</td></tr>
                                <tr><td>CD20 Loss at Relapse, n (%)</td><td>11 (40.7%)</td></tr>
                            </tbody>
                        </table>
                    </div>
                     <div class="chart-container my-4">
                        <svg id="cd20LossChart" width="280" height="230"></svg>
                        <div id="cd20LossLegend" class="legend mt-2"></div>
                    </div>
                </div>
            </div>
        </div>

        <div class="grid md:grid-cols-12 gap-x-8 gap-y-6">
            <div class="md:col-span-full">
                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results: Outcomes Based on CD20 Status at Relapse</h2>
                    <div class="grid md:grid-cols-2 gap-x-8">
                        <div>
                            <h3 class="abstract-sub-section-title">CD20-Negative Patients (n=10 evaluable<sup>*</sup>)</h3>
                             <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                                <li>Died of progressive disease: 7</li>
                                <li>Partial Response (on treatment): 2 (1 Burkitt lymphoma, 1 DLBCL)</li>
                                <li>Alive and disease-free: 1 (experienced Hodgkin lymphoma as second cancer)</li>
                            </ul>
                        </div>
                        <div>
                            <h3 class="abstract-sub-section-title">CD20-Positive Patients (N=17)</h3>
                             <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                                <li>Died: 7</li>
                                <li>Alive: 10 (6 in complete remission, 4 in partial response)</li>
                            </ul>
                        </div>
                    </div>
                     <p class="footnote-text mt-3"><sup>*</sup>Abstract reports 11/27 (40.7%) with CD20 loss, but details outcomes for 10 CD20-negative patients.</p>
                     <h3 class="abstract-sub-section-title mt-4">Hematopoietic Stem Cell Transplantation (HSCT)</h3>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>7 patients received HSCT (5 allogeneic, 2 autologous).</li>
                        <li>2 of these had a CD20-negative relapse.</li>
                        <li>3 patients, all of them having been allotransplanted, are alive and disease free.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>This retrospective data suggests that the loss of CD20 expression at relapse occurred in 40.7% of patients with R/R mature B-cell non-Hodgkin malignancies in children, adolescents, and young adults.</li>
                <li>CD20-loss is characterized by a more aggressive disease and worse outcome.</li>
                <li>Given the potential benefit of treatment with CD20 monoclonal or CD3-CD20 bispecific therapies, these observations suggest that the histological re-evaluation should be performed, whenever possible, to identify the ideal target-therapy.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>ALL, Acute Lymphoblastic Leukemia; B-ALL, B-cell Acute Lymphoblastic Leukemia; B-NHL, B-cell Non-Hodgkin Lymphoma; CD, Cluster of Differentiation; CIT, Chemoimmunotherapy; CR, Complete Remission; DLBCL, Diffuse Large B-Cell Lymphoma; Dx, Diagnosis; EFS, Event-Free Survival; HSCT, Hematopoietic Stem Cell Transplantation; IHC, Immunohistochemistry; mB-ALL, Mature B-cell Acute Lymphoblastic Leukemia; NHL, Non-Hodgkin Lymphoma; OS, Overall Survival; PD, Progressive Disease; PMBCL, Primary Mediastinal B-Cell Lymphoma; PR, Partial Response; Pts, Patients; R/R, Relapsed/Refractory; Tx, Treatment; YA, Young Adults.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Vinti L, Pianese J, Onofrillo D, et al. CD20-negative relapsed/refractory mature B-cell non-Hodgkin lymphomas (B-NHLs) and mature B-cell leukemia in children, adolescents, and young adults: a retrospective review. Abstract #PB3356 presented at the European Haematology Association (EHA) Congress. June 12â€“15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3356 | Abstract Release: 05/14/2025 | Presentation: 06/12/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>
    <script defer src="abstract_features.js"></script>
    <script>
    function drawCd20LossChart(containerId, legendContainerId) {
        const chartTitle = "CD20 Status at Relapse (N=27)";
        const chartData = [
            { status: "CD20 Loss", value: 40.7, count: 11, color: "var(--sobi-orange)" },
            { status: "CD20 Positive", value: 59.3, count: 16, color: "var(--sobi-teal)" }
        ];

        const svg = d3.select(containerId);
        const legendContainer = d3.select(legendContainerId); // For potential future legend use
        svg.selectAll("*").remove();
        if (legendContainer) legendContainer.selectAll("*").remove(); // Clear legend too

        let containerWidth = 280;
        const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
        if (chartWrapper) {
            containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.90, 220);
        }

        const svgWidth = containerWidth;
        const svgHeight = +svg.attr("height");
        const margin = { top: 30, right: 10, bottom: 10, left: 10 };
        const radius = Math.min(svgWidth - margin.left - margin.right, svgHeight - margin.top - margin.bottom) / 2;

        const g = svg.append("g")
            .attr("transform", `translate(${(svgWidth / 2)}, ${(svgHeight / 2) + margin.top / 2 - 15})`); // Centered donut

        const pie = d3.pie().sort(null).value(d => d.value);
        const path = d3.arc().outerRadius(radius - 5).innerRadius(radius - 35); // Adjusted for donut thickness
        const labelArc = d3.arc().outerRadius(radius - 20).innerRadius(radius - 20); // Adjusted for label positioning

        const arcs = g.selectAll(".arc")
            .data(pie(chartData))
            .enter().append("g")
            .attr("class", "arc");

        arcs.append("path")
            .attr("d", path)
            .attr("fill", d => d.data.color);

        arcs.append("text")
            .attr("transform", d => `translate(${labelArc.centroid(d)})`)
            .attr("dy", "0.35em")
            .style("font-size", "9px")
            .style("fill", "white")
            .style("font-weight", "bold")
            .style("text-anchor", "middle")
            .selectAll("tspan")
            .data(d => {
                return [
                    `${d.data.status.replace(" Positive", "+").replace(" Loss", "-")}`,
                    `${d.data.value.toFixed(1)}% (${d.data.count})`
                ];
            })
            .enter().append("tspan")
            .attr("x", 0)
            .attr("dy", (d, i) => i === 0 ? "-0.3em" : "1.1em") // Adjust dy for multi-line
            .text(d => d);

        svg.append("text")
            .attr("x", svgWidth / 2)
            .attr("y", margin.top / 2 + 5)
            .attr("text-anchor", "middle")
            .style("font-size", "11px") // Adjusted title font size
            .style("font-weight", "600")
            .style("fill", "var(--sobi-dark-blue)")
            .text(chartTitle);

        // Optional: Add legend if needed (currently labels are on chart)
        if (legendContainer) {
            const legendItems = legendContainer.selectAll(".legend-item")
                .data(chartData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => `${d.status} (${d.count})`);
        }
    }

    function debounce(func, wait) {
        let timeout;
        return function executedFunction(...args) {
            const later = () => { clearTimeout(timeout); func(...args); };
            clearTimeout(timeout);
            timeout = setTimeout(later, wait);
        };
    };

    const debouncedDrawCd20Chart = debounce(() => drawCd20LossChart("#cd20LossChart", "#cd20LossLegend"), 250);

    window.addEventListener('resize', debouncedDrawCd20Chart);
    document.addEventListener('DOMContentLoaded', debouncedDrawCd20Chart);
    if (document.readyState === "complete" || document.readyState === "interactive") {
         setTimeout(debouncedDrawCd20Chart, 0);
    }
    </script>
</body>
</html>